Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Rademikibart - Suzhou Connect Biopharmaceuticals

Next Previous
Drug Profile

Rademikibart - Suzhou Connect Biopharmaceuticals

Alternative Names: CBP 201

Latest Information Update: 23 Jan 2026

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Suzhou Connect Biopharmaceuticals
  • Developer Simcere Pharmaceutical Group; Suzhou Connect Biopharmaceuticals
  • Class Anti-inflammatories; Antiallergics; Antiasthmatics; Monoclonal antibodies; Skin disorder therapies
  • Mechanism of Action Interleukin 4 receptor alpha subunit antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes
  • Available For Licensing Yes - Asthma; Atopic dermatitis

Highest Development Phases

  • Preregistration Atopic dermatitis
  • Phase III Asthma
  • Phase II Chronic obstructive pulmonary disease; Rhinosinusitis
  • Phase I Respiratory tract disorders
  • No development reported Nasal polyps

Most Recent Events

  • 12 Jan 2026 Phase-I clinical trials in Respiratory tract disorders (IV)
  • 12 Aug 2025 Phase-II clinical trials in Chronic obstructive pulmonary disease (Adjunctive treatment) in Georgia, Georgia, United Kingdom, Serbia, Australia, Argentina (SC) (NCT06940154)
  • 08 Aug 2025 Phase-II clinical trials in Asthma (In adolescents, In adults, Adjunctive treatment, In the elderly) in United Kingdom, Argentina, Serbia, Australia (SC) (NCT06940141)

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top